Haystack Oncology, a Quest Diagnostics® company, will be attending the 2024 American Society of Clinical Oncology Gastrointestinal Cancers symposium (ASCO GI), which will be held January 18–20, 2024, in San Francisco, CA. The foremost global gastrointestinal (GI) cancers symposium is expected to draw 4,000 attendees, including GI specialists, oncology thought leaders, clinicians, diagnostic and drug developers, researchers, patient advocates, and others from around the world.
About Haystack MRD™
Haystack MRD helps guide tailored treatment decisions by detecting circulating tumor DNA (ctDNA) to identify any residual cancer cells after curative-intent treatment, such as surgery. Haystack uses a tumor-informed approach with a personalized test panel designed for each patient. Powered by Haystack Duo™ chemistry, the test significantly reduces noise to detect ultralow numbers of ctDNA molecules in blood. Our higher level of precision science translates to improved minimal residual disease (MRD) detection and more confident treatment decisions. With the addition of Haystack MRD, Quest Diagnostics provides a seamless transition among ultrasensitive MRD detection and a full range of oncology offerings for easier, more streamlined patient care.
Why choose Haystack MRD?
Our technology, designed by cancer research pioneers, was purpose-built to detect ultralow levels of ctDNA and offers the highest level of precision science.
Haystack MRD is powered by a highly optimized version of the ctDNA detection technology used in the DYNAMIC study to demonstrate the clinical benefit of MRD testing in stage II colon cancer patients. The DYNAMIC study was the first to provide clinical support for using ctDNA-based MRD testing to guide adjuvant therapy decisions.
Learn more at ASCO GI 2024
To connect at ASCO GI, stop by table 41 or get in touch today to schedule a meeting.